Cargando…
Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
OBJECTIVE: Very few cost-utility analyses have either evaluated direct-acting antivirals (DAAs) on hepatitis C virus (HCV) genotype 6 patients or undertaken societal perspective. Recently, DAAs have been introduced into the Vietnamese health insurance drug list for chronic hepatitis C (CHC) treatmen...
Autores principales: | Due, Ong The, Thakkinstian, Ammarin, Thavorncharoensap, Montarat, Sobhonslidsuk, Abhasnee, Wu, Olivia, Phuong, Nguyen Khanh, Chaikledkaew, Usa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491253/ https://www.ncbi.nlm.nih.gov/pubmed/32940236 http://dx.doi.org/10.1016/j.jval.2020.03.018 |
Ejemplares similares
-
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6
por: Due, Ong The, et al.
Publicado: (2019) -
Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam
por: Toi, Phung Lam, et al.
Publicado: (2021) -
Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences
por: Noparatayaporn, Prapaporn, et al.
Publicado: (2021) -
Economic evaluation of hepatitis A vaccines by income level of the country: A systematic review
por: Gurav, Yogesh Kirshnarao, et al.
Publicado: (2022) -
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)